Transferrin-coated gadolinium nanoparticles as MRI contrast agent

Molecular Imaging and Biology

Volumn 15, Issue 2, 2013, Pages 148-154

  Korkusuz, Huedayi ^a   Ulbrich, Karsten ^b   Welzel, Katerina ^b   Koeberle, Verena ^a   Watcharin, Waralee ^b   Bahr, Ute ^b   Chernikov, Valery ^c   Knobloch, Thomas ^b   Petersen, Sabine ^b   Huebner, Frank ^b   Ackermann, Hanns ^a   Gelperina, Svetlana ^d   Kromen, Wolfgang ^b   Hammerstingl, Renate ^b   Haupenthal, Joerg ^a,f   Gruenwald, Frank ^a   Fiehler, Jens ^e   Zeuzem, Stefan ^a   Kreuter, Joerg ^b   Vogl, Thomas J ^b   Piiper, Albrecht ^a   more..

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c RESEARCH INSTITUTE OF HUMAN MORPHOLOGY   (Russian Federation)

^d Nanosystem LTD   (Russian Federation)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

Biodistribution; Contrast agent; Gd DTPA human serum albumin transferrin; Human serum albumin; Nanoparticles

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM DIETHYLENETRIAMINE PENTAACETIC ACID HUMAN SERUM ALBUMIN CONJUGATE; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; TRANSFERRIN GADOLINIUM DIETHYLENETRIAMINE PENTAACETIC ACID HUMAN SERUM ALBUMIN CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG COATING; DRUG DISTRIBUTION; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

MUS;

EID: 84878506577     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0579-6     Document Type: Article

References (28)

1. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2:16
2. Anthony DC, Sibson NR, McAteer MA et al (2011) Detection of brain pathology by magnetic resonance imaging of iron oxide micro-particles. Methods Mol Biol 686:213-227
3. Enochs WS, Harsh G, Hochberg F, Weissleder R (1999) Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 9:228-232
4. Kreuter J, Shamenkov D, Petrov V et al (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317-325
5. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81
6. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71:251-256
7. Kreuter J (2012) Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). Journal of Microencapsulation. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22676632. Accessed 7 June 2012
8. Ulbrich K, Knobloch T, Kreuter J (2011) Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 19:125-132
9. Henrotte V, Muller RN, Bartholet A, Elst LV (2007) The presence of halide salts influences the non-covalent interaction of MRI contrast agents and human serum albumin. Contrast Media Mol Imaging 2:258-261
10. Weber C, Kreuter J, Langer K (2000) Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm 196:197-200
11. Gouin S, Winnik FM (2001) Quantitative assays of the amount of diethylenetriaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry. Bioconjugate Chem 12:372-377
12. Heverhagen JT (2007) Noise measurement and estimation in MR imaging experiments. Radiology 245:638-639
13. National Electrical Manufacturers Association (2001) Determination of signal-to-noise ratio (SNR) in diagnostic magnetic resonance imaging. NEMA Standards Publication, Rosslyn, Virginia, MS 1-2001
14. Lewin M, Clement O, Belguise-Valladier P et al (2001) Hepatocyte targeting with Gd-EOB-DTPA: potential application for gene therapy. Invest Radiol 36:9-14
15. Mohs AM, Zong Y, Guo J et al (2005) PEG-g-poly(GdDTPA-co-L-cystine): effect of PEG chain length on in vivo contrast enhancement in MRI. Biomacromolecules 6:2305-11
16. Karfeld-Sulzer LS, Waters EA, Davis NE et al (2010) Multivalent protein polymer MRI contrast agents: controlling relaxivity via modulation of amino acid sequence. Biomacromolecules 11:1429-36
17. Glaus C, Rossin R, Welch MJ, Bao G (2010) In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem 21:715-722
18. Oyewumi MO, Yokel RA, Jay M et al (2004) Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 95:613-626
19. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392
20. Hesselink JR, Press GA (1988) MR contrast enhancement of intracranial lesions with Gd-DTPA. Radiol Clin North Am 26:873-887
21. Russell EJ, Schaible TF, Dillon W et al (1989) Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. AJR Am J Roentgenol 152:813-823
22. Ichikawa H, Ishikawa M, Fukunaga M et al (2010) Quantitative evaluation of blood-cerebrospinal fluid barrier permeability in the rat with experimental meningitis using magnetic resonance imaging. Brain Res 1321:125-132
23. Visser CC, Stevanović S, Heleen Voorwinden L et al (2004) Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 12:145-150
24. Hombach V, Merkle N, Bernhard P et al (2010) Prognostic significance of cardiac magnetic resonance imaging: update 2010. Cardiol J 17:549-557
25. Korkusuz H, Esters P, Huebner F et al (2010) Accuracy of cardiovascular magnetic resonance in myocarditis: comparison of MR and histological findings in an animal model. J Cardiovasc Magn Reson 12:49
26. Gulyaev AE, Gelperina SE, Skidan IN et al (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564-9
27. Beitzke D, Wolf F, Edelhauser G et al (2010) Right heart dilatation in adult congenital heart disease: imaging appearance on cardiac magnetic resonance. Br J Radiol 84:188-93
28. Oudit GY, Trivieri MG, Khaper N et al (2006) Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 84:349-364